110 likes | 133 Views
Allergic Conjunctivitis is a common eye condition in which the tissue that lines the inside of eyelid and outside of the eyeball called conjunctiva, becomes inflamed.<br>
E N D
Allergic Conjunctivitis (AC) It usually happens when a person’s eyes come into contact with an allergen, a substance that makes the body’s immune system to overreact. The disease can be acute or chronic. Allergic Conjunctivitis is a common eye condition in which the tissue that lines the inside of eyelid and outside of the eyeball called conjunctiva, becomes inflamed. • 1 • 2 • 3 • 4 Allergic conjunctivitis is an exclusive term that encompasses seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal kerato conjunctivitis (VKC), and atopic kerato conjunctivitis (AKC). Unlike conjunctivitis that is caused by bacterial infection, allergic conjunctivitis is not contagious, so it cannot be transferred from one person to another. • DelveInsight © 2019 | All rights reserved
Allergic Conjunctivitis Epidemiology Allergic Conjunctivitis total diagnosed prevalent cases were found out to be 65,502,156 in 2017 among 7MM. The highest diagnosed AC prevalent cases were seen in the United States. Allergic conjunctivitis can be acute or chronic. Acute allergic conjunctivitis cases are found to be more prevalent as compared to the chronic cases. AC prevalence Allergic Conjunctivitis AC PREVALENCE Allergies conjunctivitis affect people of all ages, though they are more common in children and young adults. AC prevalence AC PREVALENCE Allergic Conjunctivitis higher diagnosed prevalence in the United States was 33,805,769 in 2017 that is expected to increase still 2028. • DelveInsight © 2019 | All rights reserved
Allergic Conjunctivitis Market Allergic Conjunctivitis therapeutic market in seven major markets (7MM)* was estimated to be USD 1617.9 million in 2017 that is expected to increase by 2028. Drugs in the clinical trials are expected to propel the growth of Allergic Conjunctivitis drug market in the upcoming years. The United States accounts for the largest Allergic Conjunctivitis market size in comparison to EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Extensive research and development activities of pharmaceutical companies to develop Allergic Conjunctivitis therapies will create a positive impact in Allergic Conjunctivitis market during the forecast period (2019-2028). Among the EU5 countries, Germany had the highest market size in 2017, while Spain had the lowest market size of Allergic Conjunctivitis. * 7MM- USA, EU-5(Germany, Spain, Italy, France and UK), Japan • DelveInsight © 2019 | All rights reserved
AC Emerging Drugs and Companies 01 Drug- ADX-102 Company-Aldeyra Therapeutics 02 Drug- PRT-2761 Company- ORA, Inc. 03 Drug- OTX-DP Company- Ocular Therapeutix, Inc 04 Drug- Bilastine Company- FaesFarma • DelveInsight © 2019 | All rights reserved
Complete Information For complete information on Allergic Conjunctivitis Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At info@delveinsight.com • DelveInsight © 2019 | All rights reserved
About DelveInsight Mission 2 1 3 About To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. Vision DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved
Services by DelveInsight PharmDelve Forecasting OpportunityAssessment Consulting ReportStore MarketIntelligence Competitive Analysis Pipeline • DelveInsight © 2019 | All rights reserved
Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved